AstraZeneca PLC AZN shares were unchanged Thursday at £120.24, on what proved to be an all-around great trading session for ...

is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. Earnings Per Share (TTM ...

AstraZeneca’s share price has fallen following unfavourable results for one of its new drugs, but others look good, and earnings prospects remain high. When investing, your capital is at risk.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Biden administration has reformed Medicare, gone after bogus drug patents and pushed pharmaceutical companies to reduce ...

AstraZeneca said on Monday it would pay up to $1.92 billion to CSPC Pharmaceutical Group Ltd in an exclusive licence ...

AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has received an average recommendation of “Moderate Buy” from the eleven ...

Hutchmed China Ltd on Wednesday said that Tagrisso plus Orpathys showed a high clinically meaningful response rate in patients with a form of lung cancer. The Shanghai-based biopharmaceutical company ...

AstraZeneca has paid CSPC Pharmaceutical Group $100 million for a preclinical cardiovascular disease drug candidate. The deal ...

Drugmaker AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical to advance the development of ...

How quickly things have changed for AstraZeneca’s (LSE: AZN) share price. Just last month, it had risen sufficiently to make the firm the first in the UK with a market capitalisation of £200bn+. Now ...